35 completed, 13 terminated, 9 unknown, 4 recruiting. 67 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 67 | Completed 35, Terminated 13, Unknown 9, Recruiting 4, Withdrawn 3, Active not recruiting 2, Not yet recruiting 1 |
| Phase 2 | 9 | Unknown 4, Completed 3, Terminated 2 |
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome Corticosteroids + Rivaroxaban, Corticosteroids alone - Behcet Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 134 | 2025-06-24 | 2026-04-23 |
| Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease Placebo plus immunosuppression, Rivaroxaban plus immunosupression - Behcet Disease, Behcet Disease and Vascular Involvement | Phase 3 | Not yet recruiting | Marmara University | 110 | 2025-04-30 | 2025-04-13 |
| A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Brepocitinib PO QD, Placebo PO QD - Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Active not recruiting | Priovant Therapeutics, Inc. | 371 | 2024-09-11 | 2026-01-12 |
| A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease Hemay005, Placebo - Behçet's Disease | Phase 3 | Recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 162 | 2023-11-13 | 2025-04-08 |
| A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis Apremilast - Behçet's Disease, Juvenile Psoriatic Arthritis | Phase 3 | Recruiting | Amgen | 48 | 2023-03-23 | 2026-11-04 |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases Triamcinolone Acetonide - Central Serous Chorioretinopathy, Irvine-Gass Syndrome | Phase 2 / Phase 3 | Unknown | Benha University | 50 | 2022-04-14 | 2022-04-20 |
| Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis Methotrexate, Adalimumab, Adalimumab+Methotrexate - Uveitis | Phase 3 | Unknown | Hospital San Carlos, Madrid | 192 | 2022-01-12 | 2023-09-21 |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior | Phase 3 | Terminated | EyePoint Pharmaceuticals, Inc. | 12 | 2021-10-13 | 2024-12-19 |
| Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease Apremilast, Placebo - Behçet Disease | Phase 3 | Recruiting | Amgen | 60 | 2021-09-09 | 2026-07-24 |
| Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease - Vogt Koyanagi Harada Disease | Phase 2 / Phase 3 | Completed | Benha University | 6 | 2020-04-01 | 2021-10-07 |
| Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Non-infectious and Idiopathic Uveitis Beta-1,3/1,6-D-Glucan Ganoderma lucidum, Placebos - Uveitis | Phase 2 / Phase 3 | Unknown | Fakultas Kedokteran Universitas Indonesia | 20 | 2020-01-21 | 2021-02-03 |
| Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA) Antitubercular treatment (RIFATER ©), Ethambutol, RIFINAH © - Uveitis, Anterior | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 116 | 2019-11-01 | 2019-10-07 |
| Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Abatacept Injection, Usual Care - Juvenile Idiopathic Arthritis | Phase 3 | Completed | Duke University | 121 | 2019-10-29 | 2026-01-23 |
| A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis Baricitinib, Adalimumab - Uveitis | Phase 3 | Active not recruiting | Eli Lilly and Company | 30 | 2019-10-16 | 2026-04-24 |
| Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF intravitreal injection of Conbercept - Uveitis, Macular Edema | Phase 2 / Phase 3 | Terminated | Peking Union Medical College Hospital | 5 | 2019-10-12 | 2022-10-25 |
| Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Adalimumab (ADA), Conventional immunosuppression (CON) - Uveitis | Phase 3 | Completed | JHSPH Center for Clinical Trials | 227 | 2019-09-16 | 2025-05-16 |
| Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Infliximab, Cyclophosphamide - Behcet's Disease, Vasculitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 53 | 2018-05-25 | 2023-07-03 |
| Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | Peking Union Medical College Hospital | 28 | 2017-06-30 | 2021-02-23 |
| Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis 4 mg CLS-TA Suprachoriodal Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 38 | 2017-04-04 | 2021-06-23 |
Showing 20 of 67. Sign in to see all of them.
Uveitis, Intermediate (22) · Uveitis, Posterior (21) · Panuveitis (18) · Behcet Syndrome (13) · Uveitis, Anterior (9) · Macular Edema (5) · Arthritis, Juvenile (4) · Chorioretinitis (2) · Oral Ulcer (2) · Uveomeningoencephalitic Syndrome (2) · Arthritis (1) · Cardiovascular Diseases (1) · Central Serous Chorioretinopathy (1) · Choroid Neoplasms (1)
Eye Diseases (67) · Uveal Diseases (67) · Panuveitis (25) · Skin and Connective Tissue Diseases (17) · Skin Diseases (14) · Vascular Diseases (14) · Cardiovascular Diseases (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (13) · Hereditary Autoinflammatory Diseases (13) · Mouth Diseases (13) · Skin Diseases, Genetic (13) · Skin Diseases, Vascular (13) · Stomatognathic Diseases (13)
Adalimumab (7) · secukinumab (7) · Methotrexate (5) · Triamcinolone Acetonide (5) · Dexamethasone (4) · Mycophenolic Acid (4) · Prednisone (4) · Cyclosporine (3) · apremilast (3) · salicylhydroxamic acid (3) · Bevacizumab (2) · Calcium Dobesilate (2) · Fluocinolone Acetonide (2) · Infliximab (2) · Interferon alpha-2 (2)
Novartis Pharmaceuticals (6) · Assistance Publique - Hôpitaux de Paris (4) · XOMA (US) LLC (4) · Amgen (3) · JHSPH Center for Clinical Trials (3) · Lux Biosciences, Inc. (3) · Sirion Therapeutics, Inc. (3) · AbbVie (prior sponsor, Abbott) (2) · Allergan (2) · Benha University (2) · Clearside Biomedical, Inc. (2) · EyePoint Pharmaceuticals, Inc. (2) · Eyegate Pharmaceuticals, Inc. (2) · Heidelberg University (2) · National Eye Institute (NEI) (2)
United States (31) · Germany (20) · United Kingdom (18) · France (17) · Spain (16) · Israel (15) · India (14) · Turkey (Türkiye) (11) · Greece (10) · Australia (9) · Canada (9) · Italy (9) · Austria (8) · Brazil (7) · South Korea (7)
Eddy Anglade, M.D. (3) · Douglas A Jabs, MD, MBA (2) · John D. Sheppard, M.D. (2) · Regina Max, MD (2) · Abu Abraham, MD (1) · Ahmed A Abdelshafy, MD (1) · Ahmed Abdelshafy, MD (1) · Andy Payne (1) · Andy Payne, PhD (1) · Christoph Deuter, Dr. (1)
PMID 23290985, PMID 28426849, PMID 36399237, PMID 36787524, PMID 12095806, PMID 17159027, PMID 17337065, PMID 17620582, PMID 19118701, PMID 20809807, PMID 21220619, PMID 23411886, PMID 23761087, PMID 27310969, PMID 27602665, PMID 28237411, PMID 28414043, PMID 29275333, PMID 29370572, PMID 30269924, PMID 31503307, PMID 31722152, PMID 32779952, PMID 33157077, PMID 33675850, PMID 34322164, PMID 34627340, PMID 34741564, PMID 35085661, PMID 35143800, PMID 35318229, PMID 35798511, PMID 36055922, PMID 36578194, PMID 36701644, PMID 36749914, PMID 37172782, PMID 37294447, PMID 37316690, PMID 37318415, PMID 38027419, PMID 38925285, PMID 39190826
2009 (10), 2014 (2), 2023 (2), U10EY024527 (2), 2019 (1), U10EY021125 (1)